National Cancer Center Hospital East was established in 1992, with the objective of generating new cancer treatments for the increasing number of cancer patients. Currently, this facility receives more than 9000 new patients annually, and has grown to be one of highest-ranking specialized hospitals in Japan. Our hospital has two missions: providing the best cancer treatment in the world and producing new, world-class cancer treatments.
Our hospitals have 425 beds including 25 beds of palliative care unit (PCU).
From a treatment perspective, our staff breaks down departmental barriers and works together laterally (under completely informed consent) to conduct the best treatment for the patient. In addition, we provide patient support from multi-occupational teams consisting of physicians, nurses, pharmacists, nutritionists, social workers, certified social insurance labor consultants, and others. These teams give patients physical, emotional, and social aid through surgery and multiple hospital visits. We are elected as the special functioning hospitals providing advanced medical care. From a research perspective, we have produced numerous global achievements as a central hub for the development of cancer-related pharmaceutical products and medical devices in Japan. We are selected as the clinical research core hospital that plays a core role in the implementation of clinical research in 2015. It is one of only 12 hospitals in Japan.
National Cancer Center Hospital East provides patients with the latest treatments and seamless, multi-faceted support, and approaches patient's varying needs with the utmost in sincerity.
We have produced top-class global achievements for promising new treatment drugs, from domestic and international first-in-human studies to clinical development studies before approval, and have made the best achievement in Japan for an investigator-initiated trial of an unapproved drug. Our staff has maintained a system whereby patients can be provided with the newest medications the world has to offer. In 2015, we launched a nationwide consortium for genomic cancer screening (SCRUM-Japan), in cooperation with medical facilities all over the country and pharmaceutical companies. Our institutes are the driving force behind construction of a system for genomic treatment of cancer in Japan, wherein the optimal treatment drug is selected according to the results of genetic analysis.
Palliative and supportive care
The department of palliative medicine provides three palliative care services: 1) outpatient clinic, 2) supportive care team and 3) palliative care unit.
- Patients with or without anti-cancer therapy consult our outpatient clinic for management of their symptoms or for support to decide where and how to spend their lives.
- This team consist of a physician, psycho-oncologist, nurse, pharmacist, dietician, physiotherapist and speech-language-hearing therapist. Our supportive care team perform a multidisciplinary approach for inpatients with various sufferings in the oncology ward.
- Our palliative care ward is an acute PCU. When patients are admitted to the PCU on urgent, they receive multidimensional assessment, rapid symptom control and intensive psychosocial care with a shorter length of stay.
We also have many ongoing researches, with the main research themes being fatigue, pain and integration of palliative care into oncology.